CHIEF FINANCIAL OFFICER · Enliven Therapeutics, Inc. · Common Stock
Side
SELL
Value
$55K
Shares
1,238
Price
$44.75
Executed
Jun 17, 2026
Disclosed
Jun 22, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Jun 17 executedJun 22, 2026 disclosed
ELVN · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 3 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Hohl Benjamin filed this Form 4 reporting a open-market sale of ELVN on Jun 17, 2026. It became public on Jun 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF FINANCIAL OFFICER
Hohl Benjamincik:0001882764
Issuer
Enliven Therapeutics, Inc.cik:0001672619
Revision history · 0
No field has changed since this record was first ingested.
